Article

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

Department of Primary Care and Populations Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK.
AIDS (Impact Factor: 6.41). 02/2001; 15(2):185-94. DOI: 10.1097/00002030-200101260-00007
Source: PubMed

ABSTRACT To describe the reasons for, and factors associated with, modification and discontinuation of highly active antiretroviral therapy (HAART) regimens at a single clinic.
A total of 556 patients who started HAART at the Royal Free Hospital were included in analyses. Modification was defined as stopping or switching any antiretrovirals in the regimen, whereas discontinuation was defined as the simultaneous stopping of all antiretrovirals included in the initial regimen. Reasons were classified as immunological/virological failure (IVF) and toxicities and patient choice/poor compliance (TPC).
The median CD4 count at starting HAART was 171 x 10(6) cells/l and viral load 5.07 log copies/ml. During a median follow-up of 14.2 months, 247 patients (44.4%) modified their HAART regimen, 72 due to IVF (29.1%) and 159 due to TPC (64.4%) and a total of 148 patients (26.6%) discontinued HAART. Older patients were less likely to modify HAART [relative hazard (RH), 0.73 per 10 years; P = 0.0008], as were previously treatment-naive patients (RH, 0.65; P = 0.0050), those in a clinical trial (RH, 0.64; P = 0.027) and those who started nelfinavir (RH, 0.57; P = 0.035). Patients who started with four or more drugs (RH, 2.21, P < 0.0001), who included ritonavir in the initial regimen (RH, 1.41; P = 0.035) or who had higher viral loads during follow-up (RH per log increase, 1.51; P < 0.0001) were more likely to modify HAART.
There was a high rate of modification and discontinuation of HAART regimens in the first 12 months, particularly due to toxicities, patient choice or poor compliance.

0 Bookmarks
 · 
68 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Persistence, continuous treatment with a prescribed medication or intervention, is an important, but underrecognized aspect of medication treatment, especially for HIV. In contrast to adherence, which measures the percentage of patient behavior to a prescribed therapy, persistence measures the duration during which a patient remains on a prescribed therapy. Decreased persistence for HIV treatment, or shorter duration on therapy, is associated with increased rates of virological failure, development of antiretroviral resistance, and increased morbidity and mortality. Additionally, frequency and duration of nonpersistent episodes rather than adherence may be a better predictor of clinical outcomes in HIV-infected patients on certain regimens. In this review, we codify the constructs of persistence and adherence, and further define persistence as either patient or regimen persistence. Furthermore, current literature on the clinical consequences of and factors associated with suboptimal persistence is summarized. Finally, methods to measure persistence as well as interventions that may improve persistence and clinical outcomes are suggested.
    AIDS (London, England) 01/2011; 25(3):279-90. · 4.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Verfgbarkeit und Anwendung von wirksamen antiretroviralen Therapieregimen haben die Mortalitt und Morbiditt der HIV-Infektion dramatisch gesenkt. Die weitestgehende Hemmung der Virusreplikation durch eine antiretrovirale Therapie (ART) verhindert die Krankheitsprogression sowie die Resistenzentwicklung, fhrt zur Rckbildung HIV-bedingter Symptome und zur klinisch relevanten Immunrekonstitution. Mittlerweile sind ber 20 antiretrovirale Substanzen in 4Medikamentenklassen zugelassen. Die Infektion ist dadurch besser behandelbar, die ART ist jedoch schwieriger geworden. Eine Vielzahl von Kombinationen ist denkbar, von denen nur eine kleine Zahl sinnvoll ist. Indikationsstellung, Auswahl der individuell am besten geeigneten Therapie, Beratung des Patienten und Therapiemonitoring erfordern ein hohes Ma an Erfahrung im Umgang mit HIV-infizierten Patienten. Unter den modernen Therapieregimen wird beim adhrenten Patienten nur noch selten ein virologisches Versagen beobachtet.The availability and use of effective antiretroviral combination therapies has dramatically decreased the morbidity and mortality of HIV infection. Almost complete suppression of viral replication by antiretroviral therapy prevents disease progression and development of resistance, as well as leading to both regression of HIV-associated symptoms and clinically relevant immune reconstitution. More than 20 antiretroviral substances in four classes have been approved. As a result of the broad therapeutic options, HIV infection can be better treated. Although a high number of combinations can be conceived, only a small number is actually applicable. The decisions to start, monitor and change therapy have become even more difficult. The indication for treatment, the selection of the most suitable therapy for an individual, the counseling of the patient, and the monitoring of the success of treatment demand a high level of knowledge and experience. Virologic failures of modern antiretroviral therapy regimens are rare in adherent patients.
    Der Hautarzt 10/2006; 57(11):961-968. · 0.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RESUMEN Este artículo de reflexión presenta los aportes de la Organización Internacional del Trabajo al mundo laboral de las personas que viven con VIH/sida. Se muestran los distintos momentos desde 1988 cuando se empieza a reconocer a nivel global que la infección afectaría de manera importante la fuerza de trabajo y se alcanza para el 2010 una norma internacional. Si bien se resalta que el papel de la Organización Internacional del Trabajo puede valorarse como positivo, aún son necesarios esfuerzos para que en general los países avancen en el reconocimiento de la capacidad productiva de las personas con la infección y se incluyan en especial los subgrupos más vulnerables, como son las mujeres. A nivel local es preciso fomentar la investigación sobre el mundo laboral de las personas con VIH/sida, con una perspectiva basada en derechos y determinación social. Palabras clave: VIH/sida, trabajo, estigma, discriminación.
    Revista Cubana de Salud Publica 09/2013; 39(4):708-717.

Full-text

View
0 Downloads
Available from